STEMI, Cardiogenic Shock, and Mortality in Patients Admitted for Acute Angiography: Associations and Predictions from Plasma Proteome Data.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
27
6
2020
medline:
16
12
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Acute myocardial infarction (AMI) remains a major cause of mortality and morbidity, and cardiogenic shock (CS) a major cause of hospital mortality after AMI. Especially for ST elevation myocardial infarction (STEMI) patients, fast intervention is essential.Few proteins have proven clinically applicable for AMI. Most proposed biomarkers are based on a priori hypothesis-driven studies of single proteins, not enabling identification of novel candidates. For clinical use, the ability to predict AMI is important; however, studies of proteins in prediction models are surprisingly scarce.Consequently, we applied proteome data for identifying proteins associated with definitive STEMI, CS, and all-cause mortality after admission, and examined the ability of the proteins to predict these outcomes. Proteome-wide data of 497 patients with suspected STEMI were investigated; 381 patients were diagnosed with STEMI, 35 with CS, and 51 died during the first year. Data analysis was conducted by logistic and Cox regression modeling for association analysis, and by multivariable LASSO regression models for prediction modeling.Association studies identified 4 and 29 proteins associated with definitive STEMI or mortality, respectively. Prediction models for CS and mortality (holding two and five proteins, respectively) improved the prediction ability as compared with protein-free prediction models; AUC of 0.92 and 0.89, respectively. The association analyses propose individual proteins as putative protein biomarkers for definitive STEMI and survival after suspected STEMI, while the prediction models put forward sets of proteins with putative predicting ability of CS and survival. These proteins may be verified as biomarkers of potential clinical relevance.
Identifiants
pubmed: 32590698
pii: 00024382-202101000-00006
doi: 10.1097/SHK.0000000000001595
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-47Informations de copyright
Copyright © 2020 by the Shock Society.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Helgestad OKL, Josiassen J, Hassager C, Jensen LO, Holmvang L, Sørensen A, Frydland M, Lassen AT, Udesen NLJ, Schmidt H, et al. Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study. Eur J Heart Fail 21 (11):1370–1378, 2019.
Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119:1211–1219, 2009.
Lyngbakken MN, Myhre PL, Røsjø H, Omland T. Novel biomarkers of cardiovascular disease: applications in clinical practice. Crit Rev Clin Lab Sci 56 (1):33–60, 2019.
Alonso-Orgaz S, Moreno-Lunaa R, Lópezb JA, Gil-Donesa F, Padialc LR, Moreud J, de la Cuestaa F, Barderasa MG. Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction. J Proteomics 109:368–381, 2014.
Vélez P, Parguiña AF, Ocaranza-Sánchez R, Grigorian-Shamagian L, Rosa I, Alonso-Orgaz S, de la Cuesta F, Guitián E, Moreu J, Barderas MG, et al. Blood coagulation, fibrinolysis and cellular haemostasis identification of a circulating microvesicle protein network involved in ST-elevation myocardial infarction. Thrombosis Haemostasis 112 (4):716–726, 2014.
Vélez P, Ocaranza-Sánchez R, López-Otero D, Grigorian-Shamagian L, Rosa I, Bravo SB, González-Juanatey JR, García Á. 2D-DIGE-based proteomic analysis of intracoronary versus peripheral arterial blood platelets from acute myocardial infarction patients: upregulation of platelet activation biomarkers at the culprit site. Proteomics Clin Appl 10 (8):851–858, 2016.
Auffret V, Cottin Y, Leurent G, Gilard M, Beer J-C, Zabalawi A, Chague F, Filippi E, Brunet D, Hacot J-P, et al. Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J 39:2090–2102, 2018.
Shmueli G. To explain or to predict? Statist Sci 25 (3):289–310, 2010.
Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, de Lemos JA, McCabe CH, Braunwald E. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358 (9293):1571–1575, 2001.
Obling L, Frydland M, Hansen R, Moller-Helgestad OK, Lindholm MG, Holmvang L, Ravn HB, Wiberg S, Thomsen JH, Jensen LO, et al. Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients. Eur Heart J Acute Cardiovasc Care 7 (1):7–15, 2018.
Beck HC, Jensen LO, Gils C, Ilondo AMM, Frydland M, Hassager C, Møller-Helgestad OK, Møller JE, Rasmussen LM. Proteomic discovery and validation of the confounding effect of heparin administration on the analysis of candidate cardiovascular biomarkers. Clin Chem 64:1474–1484, 2018.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 33 (20):2551–2567, 2012.
Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, Chichester, Brisbane, Toronto, Singapore: John Wiley & Sons, Inc.; 1987.
Benjamini Y, Hochberg Y. Controlling the false discovery rate a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289–300, 1995.
Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol 58 (1):267–288, 1996.
Meinshausen N, Bühlmann P. Stability selection (with discussion). J R Stat Soc Ser B 72:417–473, 2010.
Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. Second EditionBerlin: Springer Series in Statistics; 2009.
Koller L, Richter B, Winter MP, Sulzgruber P, Potolidis C, Liebhart F, Mörtl D, Berger R, Goliasch G, Lang I, et al. Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. J Clin Lipidol 11 (1):178–184, 2017.
Poulakou MV, Paraskevas KI, Wilson MR, Iliopoulos DC, Tsigris C, Mikhailidis DP, Perrea D. Apolipoprotein J and leptin levels in patients with coronary heart disease. In Vivo 22 (4):537–542, 2008.
Bielecka-Dabrowa A, Gluba-Brzózka A, Michalska-Kasiczak M, Misztal M, Rysz J, Banach M. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci 16 (5):10715–10733, 2015.
Xu Y, Lin H, Zhou Y, Cheng G, Xu G. Ceruloplasmin and the extent of heart failure in ischemic and nonischemic cardiomyopathy patients. Mediators Inflamm 2013:348145, 2013.
Yang S, Chen L, Sun S, Shah P, Yang W, Zhang B, Zhang Z, Chan DW, Kass DA, van Eyk JE, et al. Glycoproteins identified from heart failure and treatment models. Proteomics 15 (2–3):567–579, 2015.
Solbu MD, Kolset SO, Jenssen TG, Wilsgaard T, Løchen ML, Mathiesen EB, Melsom T, Eriksen BO, Reine TM. Gender differences in the association of syndecan-4 with myocardial infarction: The population-based Tromsø Study. Atherosclerosis 278:166–173, 2018.
Uitte de Willige S, Miedzak M, Carter AM, Lisman T, Rosendaal FR, Grant PJ, Philippou H, Ariëns RA. Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. Blood 117 (24):6694–6701, 2011.
He PP, Jiang T, OuYang XP, Liang YQ, Zou JQ, Wang Y, Shen QQ, Liao L, Zheng XL. Lipoprotein lipase: biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases. Clin Chim Acta 480:126–137, 2018.
García-Giménez JL, Romá-Mateo C, Carbonell N, Palacios L, Peiró-Chova L, García-López E, García-Simón M, Lahuerta R, Gimenez-Garzó C, Berenguer-Pascual E, et al. A new mass spectrometry-based method for the quantification of histones in plasma from septic shock patients. Sci Rep 7 (1):10643, 2017.
Kulasingam A, Hvas A-M, Grove EL, Funck KL, Kristensen SD. Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. Thromb Res 172:21–28, 2018.
Eagle KA, Lim ML, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, et al. A validated prediction model for all forms of acute coronary syndrome estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (22):2722–2733, 2004.
Wei Z, Bai J, Dai Q, Wu H, Qiao S, Xu B, Wang L. The value of shock index in prediction of cardiogenic shock developed during primary percutaneous coronary intervention. BMC Cardiovasc Disord 18 (1):188, 2018.
Bodde MC, Hermans MPJ, Jukema W, Schalij MJ, Lijfering WM, Rosendaal FR, Romijn FPHTM, Ruhaak LH, van der Laarse A, Cobbaert CM. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol 108:520–538, 2019.
Palao T, Medzikovic L, Rippe C, Wanga S, Al-Mardini C, van Weert A, de Vos J, van der Wel NN, van Veen HA, van Bavel ET, et al. Thrombospondin-4 mediates cardiovascular remodeling in angiotensin II-induced hypertension. Cardiovasc Pathol 35:12–19, 2018.